GGrantIndex
Sort

82,697 grants matching vaccine development

HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 VACCINE TRIAL IN COSTA RICA

$2,638,379
Paula Gonzalez · Fundacion Inciensa · N01 · FY2017 · CA

Structure-function analysis of infection- and vaccine-induced B-cell repertoires

$2,637,545
Stephen C Harrison · Boston Children'S Hospital · P01 · FY2017 · AI

WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY

$2,636,978
Weill Medical College Of Cornell Univ · U01 · FY2003 · HL

Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies

$2,636,665
Pamela J Bjorkman · California Institute Of Technology · P01 · FY2014 · AI

Nano Approaches to Modulate Host Cell Response for Cancer Therapy

$2,636,624
Leaf Huang · Univ Of North Carolina Chapel Hill · U54 · FY2017 · CA

Pushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogens

$2,635,377
Christopher Parks · International Aids Vaccine Initiative · P01 · FY2018 · AI

SPORE IN BREAST CANCER

$2,634,576
University Of Alabama At Birmingham · P50 · FY2001 · CA

San Francisco Bay Clinical Trials Unit

$2,634,428
Susan Buchbinder · Public Health Foundation Enterprises · UM1 · FY2019 · AI

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)

$2,633,037
Joel Moss · National Heart, Lung, And Blood Institute · ZIA · FY2021 · HL

Influenza and Emerging Infectious Diseases

$2,632,949
Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI

Influenza and Emerging Infectious Diseases

$2,632,754
Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine

$2,632,704
Andrea L Cox · Johns Hopkins University · U19 · FY2021 · AI

Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine

$2,631,174
Andrea L Cox · Johns Hopkins University · U19 · FY2022 · AI

Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine

$2,630,987
Andrea L Cox · Johns Hopkins University · U19 · FY2024 · AI

Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine

$2,630,982
Andrea L Cox · Johns Hopkins University · U19 · FY2023 · AI

Mechanisms of naturally-acquired immunity to malaria

$2,630,010
Peter Crompton · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Malaria Vaccine: BSAM

$2,629,000
Louis Miller · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

Nanotechnology enabled quantitative imaging of dendritic cell anti-cancer vaccines

$2,628,974
Carlos M Rinaldi-Ramos · University Of Florida · R01 · FY2025 · CA

Northwestern University Clinical Trial Unit

$2,628,944
Robert L. Murphy · Northwestern University At Chicago · UM1 · FY2012 · AI

Integrative Immunogen Design and Testing

$2,628,877
Erica Ollmann Saphire · Brigham And Women'S Hospital · P01 · FY2021 · AI

Structural vaccinology guided development of a universal CoV vaccine utilizing nucleic acid delivered nanoparticles

$2,626,814
David B. Weiner · Wistar Institute · P01 · FY2022 · AI

Integrated Support Services

$2,626,784
Joan Elizabeth Nichols · University Of Texas Med Br Galveston · UC7 · FY2012 · AI

Understanding Papillomavirus Virion Proteins and Vaccines

$2,626,564
John T. Schiller · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

The Johns Hopkins University-Blantyre Clinical Trials Unit

$2,626,268
Taha E Taha · Johns Hopkins University · UM1 · FY2021 · AI

COVID-19: Assay Development, HTS and Drug Repurposing to identify potential therapeutics against SARS-CoV-2

$2,626,150
Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2023 · TR